Explore the complexities of Ulcerative Colitis, its causes, diagnostic methods, and breakthrough treatments for better ...

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

J&J’s guselkumab gets EU approval for ulcerative colitis, offering new hope for patients who don’t respond to current ...

Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the European Commission (EC) to treat adults with ulcerative colitis (UC).

Sylvie Grégoire, Chair of Abivax Board of Directors, commented: “We are delighted to welcome Dominik to the Board at such a pivotal moment for Abivax. His extensive background in global medical ...

Appendectomy may be a useful addition to medical therapy for preventing relapse of ulcerative colitis among patients in ...

The University of Central Lancashire is co-leading the first and largest human trial of its kind. A study found that patients ...

Appendicectomy combined with standard medical therapy is superior to standard medical therapy alone in maintaining remission ...

Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.